EBIT (Annual)

EBIT: Income before interest and taxes.

Zealand Pharma A/S (ZLDPF) had EBIT of $1.05B for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$1.40B
Net Income	$977.29M
Cost of Goods Sold	$0.12M
Gross Profit	$1.40B
Operating Expenses	$341.47M
Operating Income	$1.05B
Non-Operating Income/Expense	$6.30M
Pre-Tax Income	$1.06B
Normalized Pre-Tax Income	$1.06B
Income after Taxes	$977.29M
Income from Continuous Operations	$977.29M
Consolidated Net Income/Loss	$977.29M
Normalized Income after Taxes	$977.29M
EBIT	$1.05B
EBITDA	$1.06B
Weighted-Average Shares Outstanding (Basic)	70.50M
Weighted-Average Shares Outstanding (Diluted)	71.55M
Earnings per Share (EPS) (Basic)	$13.86
Earnings per Share (EPS) (Diluted)	$13.66
Balance Sheet Financials
Current Assets	$2.37B
Property, Plant, and Equipment	$10.58M
Long-Term Assets	$42.19M
Total Assets	$2.41B
Current Liabilities	$100.68M
Long-Term Debt	$45.86M
Long-Term Liabilities	$68.62M
Total Liabilities	$169.29M
Common Equity	$2.25B
Tangible Shareholders Equity	$2.24B
Shareholders Equity	$2.25B
Common Shares Outstanding	71.52M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$988.93M
Cash Flow from Investing Activities	$-340.42M
Cash Flow from Financial Activities	$-57.26M
Beginning Cash	$109.92M
End Cash	$692.89M
Increase/Decrease in Cash	$582.97M
Stock-Based Compensation	$17.55M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	23.57
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.02
Debt to Equity Ratio	0.02
Gross Margin	99.99%
Operating Margin	75.52%
EBIT Margin	75.52%
EBITDA Margin	75.82%
Pre-Tax Profit Margin	75.98%
Profit Margin	70.05%
Free Cash Flow	$987.46M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.58
Inventory Turnover	--
Receiveable Turnover	28.82
Days Sales in Receivables	12.66
Return on Equity	43.52%
Return on Tangible Equity	43.66%
Return on Assets	40.47%
Return on Investments	42.65%
Book Value Per Share	$31.40
Free Cash Flow per Share	$13.80
Operating Cash Flow per Share	$13.82

Data from Zacks Investment Research, Inc.